Sugi Predict

Sugi Predict / Compounds / SCHEMBL907057

SCHEMBL907057

SCHEMBL907057

COc1cc2c(Nc3ccc(Cl)c(Cl)c3)ncnc2cc1OC1CCCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 17/20 1.00
▸ EPHA2 P29317 15/20 1.00
▸ EPHB4 P54760 15/20 1.00
▸ ERBB2 P04626 9/20 0.78
▸ FLT1 P17948 4/20 0.78
▸ EGFR P00533 4/20 0.72
▸ AURKA O14965 1/20 0.64
▸ INSR P06213 1/20 0.64
▸ FBP1 P09467 1/20 0.64
▸ PDGFRB P09619 1/20 0.64
▸ FLT4 P35916 1/20 0.64
▸ CLK1 P49759 1/20 0.64
▸ TEK Q02763 1/20 0.64
▸ AURKB Q96GD4 1/20 0.64
▸ RET P07949 1/20 0.64
▸ KIF5B P33176 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL666931 0.90 KDR (0.82) KDREPHA2EPHB4ERBB2FLT1
SCHEMBL22598591 0.89 KDR (0.80) KDREPHA2EPHB4ERBB2FLT1
SCHEMBL2100447 0.88 KDR (0.80) KDREPHA2EPHB4ERBB2FLT1
SCHEMBL1793868 0.88 EPHA2 (1.00) KDREPHA2EPHB4ERBB2FLT1
SCHEMBL906592 0.88 EPHA2 (1.00) KDREPHA2EPHB4ERBB2FLT1
Hydrochloric Acid SCHEMBL906981 0.87 EPHA2 (0.98) KDREPHA2EPHB4ERBB2FLT1
Hydrochloric Acid SCHEMBL906979 0.87 EPHA2 (0.98) KDREPHA2EPHB4ERBB2FLT1
SCHEMBL4387173 0.85 EPHB4 (0.79) KDREPHA2EPHB4ERBB2FLT1
SCHEMBL6110059 0.85 EPHB4 (0.79) KDREPHA2EPHB4ERBB2FLT1
SCHEMBL6110047 0.85 EPHB4 (0.79) KDREPHA2EPHB4ERBB2FLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060069077-A1 Receptor-type kinase modulators and methods of use KADMON CORPORATION, LLC 2006-03-30 — — US claimed
US-10266518-B2 Solid dosage formulations of substituted quinazoline receptor-type kinase modulators and methods of use thereof SYMPHONY EVOLUTION, INC. (US) 2019-04-23 — — US disclosed
US-10266518-B2 Solid dosage formulations of substituted quinazoline receptor-type kinase modulators and methods of use thereof SYMPHONY EVOLUTION, INC. (US) 2019-04-23 — — US disclosed
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP disclosed
US-20180118724-A1 Receptor-Type Kinase Modulators and Methods of Use SYMPHONY EVOLUTION, INC. (US) 2018-05-03 — — US disclosed
US-20180118724-A1 Receptor-Type Kinase Modulators and Methods of Use SYMPHONY EVOLUTION, INC. (US) 2018-05-03 — — US disclosed
US-20180118724-A1 Receptor-Type Kinase Modulators and Methods of Use SYMPHONY EVOLUTION, INC. (US) 2018-05-03 — — US disclosed
US-9796704-B2 Substituted quinazolines as receptor-type kinase inhibitors SYMPHONY EVOLUTION, INC. (US) 2017-10-24 — — US disclosed
US-9796704-B2 Substituted quinazolines as receptor-type kinase inhibitors SYMPHONY EVOLUTION, INC. (US) 2017-10-24 — — US disclosed
US-9796704-B2 Substituted quinazolines as receptor-type kinase inhibitors SYMPHONY EVOLUTION, INC. (US) 2017-10-24 — — US disclosed
EP-2280003-A2 Process for preparing receptor-type kinase modulators Symphony Evolution, Inc. (US) 2011-02-02 — — EP disclosed
EP-2277867-A2 Compounds, pharmaceutical compositions thereof and their use in treating cancer Symphony Evolution, Inc. (US) 2011-01-26 — — EP disclosed
US-20090318373-A1 Receptor-type kinase modulators and methods of use KADMON CORPORATION, LLC 2009-12-24 — — US disclosed
US-20090318373-A1 Receptor-type kinase modulators and methods of use KADMON CORPORATION, LLC 2009-12-24 — — US disclosed
US-20090318373-A1 Receptor-type kinase modulators and methods of use KADMON CORPORATION, LLC 2009-12-24 — — US disclosed
US-7576074-B2 Receptor-type kinase modulators and methods of use KADMON CORPORATION, LLC 2009-08-18 — — US disclosed
US-7576074-B2 Receptor-type kinase modulators and methods of use KADMON CORPORATION, LLC 2009-08-18 — — US disclosed
US-7576074-B2 Receptor-type kinase modulators and methods of use KADMON CORPORATION, LLC 2009-08-18 — — US disclosed
US-20080166359-A1 Methods of using MEK inhibitors EXELIXIS, INC. 2008-07-10 — — US disclosed
US-20060069077-A1 Receptor-type kinase modulators and methods of use KADMON CORPORATION, LLC 2006-03-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060069077-A1 Receptor-type kinase modulators and methods of use EGFR, EPHA2, ERBB4 KDR 17/4885EPHA2 2/4885EPHB4 16/4885
US-10266518-B2 Solid dosage formulations of substituted quinazoline receptor-type kinase modulators and methods of use thereof EGFR, ERBB4, ERBB3 KDR 16/4885EPHA2 4/4885EPHB4 17/4885
US-20180118724-A1 Receptor-Type Kinase Modulators and Methods of Use EGFR, EPHA2, ERBB4 KDR 17/4885EPHA2 2/4885EPHB4 16/4885
US-20090318373-A1 Receptor-type kinase modulators and methods of use EGFR, EPHA2, ERBB4 KDR 17/4885EPHA2 2/4885EPHB4 16/4885
US-20080166359-A1 Methods of using MEK inhibitors BRAF, NRAS, KRAS KDR 1023/4885EPHA2 977/4885EPHB4 1441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.